BofA lowered the firm’s price target on McKesson (MCK) to $650 from $680 and keeps a Buy rating on the shares. Specialty will remain a key growth area for drug distributors Cardinal Health (CAH), Cencora (COR) and McKesson, but the pace of acquisitions may slow in 2025 given the limited number of specialty assets in the market, the analyst tells investors in a 2025 outlook note for the Healthcare Tech and Distribution group.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MCK:
- Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
- McKesson price target raised to $642, named a ‘Top Pick’ at Morgan Stanley
- McKesson price target raised to $641 from $535 at Wells Fargo
- Cardinal Health assumed with an Outperform at Mizuho
- McKesson assumed with a Neutral at Mizuho
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
